Cerveau Technologies, Inc

Lantheus Cerveau, a subsidiary of Lantheus Holdings, Inc., is a leading provider of information and technology to researchers and clinicians in the field of brain health. Their mission is to accelerate the development and approval of effective therapies for Alzheimer's disease and other neurodegenerative diseases by providing access to biomarkers of neurological pathologies, essential enabling tools, and information technology. They specialize in the use of molecular imaging, particularly their core asset MK-6240, a next-generation Tau PET imaging biomarker, which has been extensively used in human clinical studies by pharmaceutical companies and academic centers.

Lantheus Cerveau's key competencies include partnership network development and maintenance with pharma, academia, and regional distributors, seamless technology transfer to establish a worldwide production network of impeccable quality, and robust quality, regulatory affairs, and data management. They have an exclusive worldwide license from Merck for MK-6240 and have established a global network of distribution sites capable of producing the biomarker under stringent quality standards. This makes MK-6240 suitable for use in scientifically and regulatorily demanding pharma and academic clinical trials, providing high-resolution images with high sensitivity for Tau protein and minimal binding to non-Tau pathologies in the brain.

Generated from the website